Full Text View
Tabular View
No Study Results Posted
Related Studies
Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease
This study has been completed.
First Received: April 4, 2001   Last Updated: March 3, 2008   History of Changes
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00013975
  Purpose

This study will measure and compare the levels of endothelial progenitor cells (EPCs) in the blood of people with and without risk factors for atherosclerosis (hardening of the arteries) to see if there is a relationship between these cells and cardiovascular risk factors such as smoking, high cholesterol level and high blood pressure.

Healthy male volunteers between the ages of 21 and 55 years with and without heart disease risk factors may be eligible for this study. Candidates must have no evidence of coronary or peripheral vascular disease, proliferative retinopathy, or other chronic disease and no history of cancer, migraine-type headache, cluster headache, raised intraocular pressure, raised intracranial pressure, hyperthyroidism.

Participants will undergo the following procedures at the NIH Clinical Center:

  • Medical history and physical examination
  • Blood tests to measure EPC level and various risk and growth factors
  • Brachial reactivity study - This ultrasound study tests how well the subject's arteries widen. The subject rests on a bed for 30 minutes. An ultrasound measuring device is placed over the artery just above the elbow. The size of the artery and blood flow through it are measured before and after inflating a pressure cuff around the forearm. The pressure cuff stops the flow of blood to the arm for a few minutes. After a 15-minute rest, the drug nitroglycerin is sprayed under the subject's tongue. Before the nitroglycerin spray and 3 minutes after it, the size of the artery and blood flow through it are measured again.

Condition
Coronary Arteriosclerosis

MedlinePlus related topics: Cholesterol Coronary Artery Disease Heart Diseases High Blood Pressure Smoking Smoking and Youth
U.S. FDA Resources
Study Type: Observational
Official Title: Endothelial Progenitor Cells and Risk Factors for Coronary Artery Disease

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 120
Study Start Date: March 2001
Estimated Study Completion Date: March 2003
Detailed Description:

Evidence suggests that risk factors for atherosclerosis contribute to atherogenesis by causing endothelial injury. However, little is known about determinants of endothelial cell repair and regeneration. We propose that mobilization of endothelial progenitor cells (EPCs) constitutes one mechanism for ongoing endothelial repair. EPCs are a bone marrow derived cell population that can be isolated from peripheral blood. Among human peripheral mononuclear cells, EPCs are relatively abundant with an estimated frequency of 1 in 500 to 1 in 1000 cells. Evidence suggests that EPCs can participate in angiogenesis under pathophysiological circumstances. Under normal conditions, however, adult organisms undergo little if any active angiogenesis.

One explanation for this set of observations is that high circulating levels of EPCs may exist to allow these cells to participate in functions beyond angiogenesis. We hypothesize that one such function is in the repair of ongoing endothelial injury. To test this hypothesis, we will measure peripheral blood EPC activity by ascertaining the number of EPC colony forming units from peripheral blood sampling. We intend to correlate this biological determinant with the degree of endothelial dysfunction assessed by flow-mediated brachial artery reactivity, and an atherosclerotic risk stratification method developed by the Framingham study. We hypothesize that a correlation will exist between the atherosclerotic risk profile, endothelial function and EPC activity and that the EPC activity will therefore become a novel surrogate biological marker for cumulative cardiovascular risk.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

Men: aged 21 and above with or without cardiovascular risk factors

Women - post menopausal (based on clinical history) with and without cardiovascular risk factors

EXCLUSION CRITERIA:

Pre-menopausal women

History of cancer

Evidence of proliferative retinopathy

History of migraine-type headache

History of cluster headache

History of raised intraocular pressure

History of raised intracranial pressure

Hypersensitivity to organic nitrates

History of hyperthyroidism

Any intercurrent illness

Any other chronic disease not including cardiovascular risk factors.

No current medications including vitamins for at least 1 week.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00013975

Locations
United States, Maryland
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
Study ID Numbers: 010119, 01-H-0119
Study First Received: April 4, 2001
Last Updated: March 3, 2008
ClinicalTrials.gov Identifier: NCT00013975     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Framingham Risk Scoring
Brachial Artery Reactivity
EPC Colony Assay
Healthy Volunteer
Atherosclerosis Risk Factors
Cholesterol
Hypertension
Smoking
Diabetes
Postmenopausal
Heart Disease Risk Factors
Risk Factors

Study placed in the following topic categories:
Atherosclerosis
Arterial Occlusive Diseases
Heart Diseases
Myocardial Ischemia
Diabetes Mellitus
Vascular Diseases
Arteriosclerosis
Ischemia
Healthy
Coronary Disease
Smoking
Coronary Artery Disease
Hypertension

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Cardiovascular Diseases
Arteriosclerosis
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 06, 2009